We did two accuracy studies. Publications can be found here and here (#599, Herzig et al.).
In the latest randomized clinical trial (RCT), the medical impact of SNAQ on glycemic outcome measures (time in range, time above range, time below range, mean glucose, glucose variability) was analyzed when SNAQ is used together with the latest insulin pump devices and algorithms (Automated Insulin Delivery):
The intervention period was 3 weeks and included 44 participants with Type 1 Diabetes. Devices used: Medtronic 780g, mylife CamAPS FX, Tandem Control IQ, DBLG1.
Confidential
The improvement in Time-in-Range (primary endpoint) was 6.6 percentage points (95% CI 2.85 to 10.28%, p<0.001). %time spent in hypoglycaemia was low in either group, without significant between-group differences. No study-related SAEs occurred in this trial.
Three weeks of SNAQ use (applied for 1.7 ± 1 meals per day) compared to control resulted in a statistically significant difference in TIR, %time above range, mean glucose and glucose variability, all in favor of SNAQ.
Further results will be presented at the EASD Annual Conference in September.
Currently, 100k installs and 6-8k monthly active users.
*Pen & Pump are defined as requiring bolus insulin (= does not include basal only users)
→ Real world data shows similar usage as in study
We recently analyzed real world data of people with Type 2 Diabetes on multiple daily insulin injection therapy using SNAQ (n=175):